TSHA Stock Risk & Deep Value Analysis
Taysha Gene Therapies Inc
DVR Score
out of 10
What You Need to Know About TSHA Stock
We analyzed Taysha Gene Therapies Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran TSHA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
TSHA Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk for Taysha is the clinical failure of TSHA-102 in pivotal trials, either due to unexpected safety concerns or insufficient efficacy. This would undermine the core investment thesis, leading to substantial value erosion and potential liquidation or significant restructuring.
Risk Matrix
Overall
Aggressive
Financial
High
Market
High
Competitive
Medium
Execution
Medium
Regulatory
High
Red Flags
- ⚠
Widened net loss of $42.4 million in Q1 2026 with $0 revenue, indicating a high cash burn rate.
- ⚠
Reliance on a single lead asset (TSHA-102) for near-term value creation.
- ⚠
Future capital raises and potential dilution are highly probable given current burn rate and pre-revenue status.
Upcoming Risk Events
- 📅
Negative clinical trial results for TSHA-102
- 📅
Manufacturing delays or challenges impacting BLA submission
- 📅
Further significant share dilution without corresponding value creation
When to Reconsider
- 🚪
Exit if TSHA-102 pivotal trial data reports unexpected serious adverse events or fails to meet primary endpoints.
- 🚪
Sell if the company announces significant manufacturing setbacks delaying BLA submission by more than 6 months.
- 🚪
Re-evaluate position if cash runway significantly shortens below 12 months without clear funding plan.
Unlock TSHA Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
Taysha Gene Therapies is a speculative investment targeting 10x growth potential through its gene therapy pipeline for rare CNS disorders. The bull case is anchored by TSHA-102's positive safety profile, progress in pivotal trials, and the strategic Astellas partnership. Successful completion of trials and subsequent BLA submission, coupled with the company's extended cash runway, positions Taysha to capture a significant share of the Rett syndrome market and drive substantial shareholder value.
Is TSHA Stock Undervalued?
Unlock the full AI analysis for TSHA
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
TSHA Price Targets & Strategy
12-Month Target
$18.00
Bull Case
$28.00
Bear Case
$3.00
Valuation Basis
Based on successful completion of pivotal trials (REVEAL, ASPIRE) and BLA-enabling manufacturing (Q4 2026), projecting a $5.2B market cap on 287.3M shares outstanding = $18.00/share, pricing in significant de-risking of TSHA-102.
Entry Strategy
Consider dollar-cost averaging between $5.50-$6.00, looking for consolidation around current levels or minor pullbacks.
Exit Strategy
Take initial profits at $15-$18, with a stop-loss order placed below $4.50 to manage downside risk.
Portfolio Allocation
7-15% for aggressive risk tolerance, reflecting its high-risk, high-reward profile.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is TSHA Financially Healthy?
Valuation
P/E Ratio
-8.90
Forward P/E
3.00
EV/EBITDA
-23.10
PEG Ratio
-0.21
Price/Book
3.30
Price/Sales
102.00
Profitability
Operating Margin
-782.50%
Net Margin
-780.33%
Return on Equity
-56.07%
Revenue Growth
3.42%
EPS
$-0.38
Balance Sheet
Current Ratio
12.23
Quick Ratio
12.10
Debt/Equity
0.20
Cash & Equivalents
$1.10B
Cash Flow
Operating Cash Flow
-$175.00M
Free Cash Flow
-$185.00M
EBITDA
-$79.00M
Other
Beta (Volatility)
1.30
Does TSHA Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The moat's durability hinges on TSHA-102's successful clinical and regulatory pathway, establishing a strong first-mover advantage and standard of care in Rett syndrome. The complexity of gene therapy development and the specialized expertise in CNS disorders enhance this durability.
Moat Erosion Risks
- •Failure of TSHA-102 clinical trials or significant manufacturing setbacks.
- •Emergence of a superior competing gene therapy or alternative treatment for Rett syndrome.
- •Challenges to Taysha's intellectual property rights or patent expiry.
TSHA Competitive Moat Analysis
Sign up to see competitive advantages
TSHA Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral to Cautiously Bullish. Retail investor sentiment is likely driven by clinical updates and the speculative nature of gene therapy stocks.
Institutional Sentiment
Positive, evidenced by the Schedule 13G/A filing by RTW Investments and the stock hitting a 12-month high on May 6, 2026.
Insider Activity (Form 4)
A Schedule 13G/A filing by RTW Investments, LP on May 15, 2026, indicates an amendment to their beneficial ownership, suggesting continued or adjusted institutional interest in the company.
Options Flow
Normal options activity, with no specific unusual activity reported in the provided sources.
Earnings Intelligence
Next Earnings
Estimated early-August 2026
Surprise Probability
Medium
Historical Earnings Pattern
Price reactions are primarily driven by clinical updates, regulatory milestones, and cash runway announcements rather than quarterly financial results for this clinical-stage biotech.
Key Metrics to Watch
Competitive Position
Top Competitor
Sarepta Therapeutics (SRPT)
Market Share Trend
Not applicable as the company is pre-commercialization. Focus is on gaining market share upon product launch.
Valuation vs Peers
Difficult to compare directly due to Taysha's pre-revenue status. Its valuation is largely based on pipeline potential and risk-adjusted NPV of future revenue, rather than current earnings or sales multiples, often trading at a discount to commercial-stage gene therapy companies but a premium on potential.
Competitive Advantages
- •Proprietary AAV gene therapy platform specialized for CNS delivery.
- •Strategic partnership with Astellas Pharma providing validation and funding.
- •Potential first-in-class therapy for Rett syndrome, addressing a high unmet medical need.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive TSHA Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings (Estimated early-August 2026)
- •Completion of dosing in REVEAL pivotal trial (Expected Q2 2026)
- •Completion of dosing in ASPIRE trial (Expected Q2 2026)
- •BLA-enabling PPQ campaign completion (Expected Q4 2026)
Medium-Term (6-18 months)
- •Topline data readouts from REVEAL and ASPIRE trials
- •Biologics License Application (BLA) submission for TSHA-102 (if manufacturing successful)
- •Potential milestone payments from Astellas partnership
Long-Term (18+ months)
- •Regulatory approval and commercial launch of TSHA-102 for Rett syndrome
- •Pipeline advancement for other rare CNS disorders
- •Label expansion for TSHA-102 into broader patient populations
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for TSHA?
- ✓
Consistent positive safety and efficacy data from ongoing TSHA-102 trials.
- ✓
Timely completion of BLA-enabling manufacturing and BLA submission.
- ✓
Further strategic partnerships or pipeline advancements for other rare CNS indications.
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Taysha Gene Therapies Inc Makes Money
Taysha Gene Therapies is a clinical-stage biotechnology company focused on developing and potentially commercializing adeno-associated virus (AAV)-based gene therapies for severe monogenic central nervous system (CNS) diseases. The company currently generates no revenue and operates by investing heavily in research and development to advance its therapeutic candidates through preclinical and clinical trials. Its business model relies on achieving regulatory approvals for its therapies, most notably TSHA-102 for Rett syndrome, to then generate revenue through product sales, potentially alongside milestone payments and royalties from strategic partnerships.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Taysha Gene Therapies Inc (TSHA)?
As of May 17, 2026, Taysha Gene Therapies Inc has a DVR Score of 8.0 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Taysha Gene Therapies Inc?
Taysha Gene Therapies Inc's market capitalization is approximately $1.7B..
What is the risk level for TSHA stock?
Our analysis rates Taysha Gene Therapies Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of TSHA?
Taysha Gene Therapies Inc currently has a price-to-earnings (P/E) ratio of -8.9. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Taysha Gene Therapies Inc's revenue growing?
Taysha Gene Therapies Inc has reported revenue growth of 3.4%. The company is growing at a moderate pace.
Is TSHA stock profitable?
Taysha Gene Therapies Inc has a profit margin of -780.3%. The company is currently unprofitable.
How often is the TSHA DVR analysis updated?
Our AI-powered analysis of Taysha Gene Therapies Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 17, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for TSHA (Taysha Gene Therapies Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.